Desmedt C, Fornili M, Clatot F, et al. - Researchers performed reanalysis of clinical trial data to determine if the efficacy of docetaxel-based chemotherapy vs non-docetaxel–based chemotherapy differ in cases with breast cancer by their baseline BMI. In this retrospective analysis, they assessed data from all of the patients in the adjuvant BIG 2-98 trial (N = 2,887) comparing non-docetaxel– to docetaxel-containing chemotherapy. Outcomes revealed a differential response to docetaxel according to BMI, which supports performing a body composition–based re-evaluation of the risk-benefit ratio of the use of taxanes in breast cancer.